Short-Term Price Performance and Market Comparison
The stock’s recent trajectory has been notably weak. Over the past week, Kilitch Drugs has declined by 5.75%, substantially underperforming the Sensex, which recorded a modest loss of 0.63% during the same period. The one-month performance is even more concerning, with the stock falling 15.10% while the Sensex gained 2.27%. Year-to-date, Kilitch Drugs has barely moved, registering a negligible 0.02% increase compared to the Sensex’s robust 8.91% gain. Over the last year, the stock has declined by 4.39%, whereas the benchmark index rose by 4.15%. These figures highlight a clear divergence between Kilitch Drugs and the broader market, signalling investor caution or negative sentiment specific to the company.












